Stephen OHara, OptiBiotix Health Plc CEO said: ‘This report in the Express is another article highlighting concerns from the side affects from statins. This has created interest from healthcare providers in the use of agents which replace or supplement existing treatment options: particularly where mechanisms of action work complementary to existing treatments. OptiBiotix’s microbial strain has shown significant reduction in LDL cholesterol in clinical studies and has a mechanism of action complementary to statins. This suggests combinational treatment may have the potential to lower statin dosage, reduce cost, and limit side effects whilst improving statin compliance’
A few weeks back you may recall that we published an article on the use of Statins and the potential risk of increasing heart attacks. There was overwhelming evidence to suggest that these drugs accelerate the hardening of the arteries and could cause heart failure.
Now a new study has has found that statins users almost double the risk of diabetes and up to a twofold risk of debetic complications. The study which was conducted over a ten year period examined 25,970 patients found that statins users had a higher indcidence of diabetes and also weight gain. The study which was published in the Journal of General Internal Medicine confirms a link long suspected between statin use and diabetes.
If companies like OptiBiotix Health Plc can reduce the intake of statins then not only does this limit side effects & reduce costs it would prolong life expectancy in patients.
